Operates three pharmaceutical businesses that together generated Rs 8,869 crore in FY26. The largest is CDMO (Contract Development and Manufacturing Organization), which produced Rs 4,915 crore or 55% of FY26 revenue by manufacturing active ingredients and drug products on behalf of global pharma and biotech customers; the pipeline includes 35+ Phase 3 molecules and antibody-drug conjugate (ADC) capacity at the Grangemouth facility. The Critical Care segment (formerly Complex Hospital Generics) generated Rs 2,703 crore or 30% of revenue and supplies hospital-administered generics such as Sevoflurane (inhalation anaesthesia) and Gablofen (Baclofen pre-filled syringes, where the brand holds a 77% share of the US Baclofen PFS/vial market); the Kenalog acquisition expands this portfolio with supplies starting Q2 FY27. India Consumer Healthcare contributed Rs 1,274 crore or 14% of FY26 revenue (growing 17% YoY), selling OTC brands through retail and its Wellify.in D2C platform, with Power brands contributing 43% of segment sales. The cost base is dominated by employees at Rs 2,415.92 crore (27.2% of revenue) and materials at Rs 1,995.85 crore (22.5%), with capex of Rs 890.02 crore in FY26 including a US$90 million commitment to expand the Lexington and Riverview sites. Q1 FY27 revenue rose 17% YoY to Rs 2,270 crore with EBITDA margin expanding 400 bps to 12.5%, though the consolidated business remained loss-making. AR · MarketPing reader · 2026-08-03
Revenue streams, as the annual report describes them. CDMO (55%), Critical Care (30%), Consumer Healthcare (14%). Asset-heavy pharmaceutical manufacturer and service provider across CDMO, hospital generics and consumer healthcare
| ₹ crore · consolidated | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
| Revenue | 7,082 | 8,171 | 9,151 | 8,869 |
| EBITDA (ex other income) | 621 | 1,133 | 1,445 | 725 |
| margin % | 8.8 | 13.9 | 15.8 | 8.2 |
| Owners' profit | (186) | 18 | 91 | (326) |
| EPS, as reported (₹) | (1.57) | 0.14 | 0.69 | (2.46) |
| ROE % · ROCE % | (2.8) · 1.6 | 0.2 · 5.2 | 1.1 · 6.4 | (4.0) · 0.8 |
| Debt / equity (x) | 0.81 | 0.58 | 0.58 | 0.67 |
| Cash from operations | 484 | 1,005 | 892 | 1,653 |
| Capex | (965) | (712) | (664) | (890) |
| ₹ crore | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 2,242 | 2,204 | 2,754 | 1,934 | 2,044 | 2,140 | 2,752 | 2,270 |
| Profit before tax | 103 | 50 | 257 | (98) | (61) | (104) | 29 | (27) |
| Net profit | 23 | 4 | 154 | (82) | (99) | (136) | (9) | (69) |
| EPS (₹) | 0.17 | 0.03 | 1.16 | (0.62) | (0.75) | (1.03) | (0.07) | (0.52) |
| Company | M.cap ₹ cr | P/E | P/B | EV/EBITDA | ROE % | ROCE % | Rev CAGR 5y % | EBITDA m. % |
|---|---|---|---|---|---|---|---|---|
| SUN PHARMACEUTICAL IND L | 4,41,471 | 36.5 | 5.26 | 23.7 | 13.7 | 17.5 | 11.8 | 32.3 |
| DIVI S LABORATORIES LTD | 2,47,033 | 84.6 | 14.74 | 63.7 | 15.3 | 18.8 | 8.7 | 42.8 |
| TORRENT PHARMACEUTICALS L | 1,68,062 | 79.3 | 9.56 | 41.5 | 12.2 | 8.0 | 11.8 | 33.1 |
| ZYDUS LIFESCIENCES LTD | 1,11,686 | 24.9 | 3.78 | 14.5 | 17.3 |
| Date · filing | Category | Importance | 1-day % | 5-day % |
|---|---|---|---|---|
| 8 Sept 2026 · Piramal Pharma to hold institutional investor meetings in UK | board shareholder meetings | low | — | — |
| 3 Sept 2026 · ESG rating rises to 65 from 64 for FY26 | credit debt | medium | — | — |
| 26 Aug 2026 · Deutsche Bank re-pledges 7.43% Piramal Pharma shares; total pledge back to 18.01% voting | ownership changes | medium | — | — |
| 24 Aug 2026 · Piramal Pharma files FY2026 Sustainability Report with BSE and NSE | general | low | — | — |
| 18 Aug 2026 · Piramal Pharma acquires additional 40.67% stake in Yapan Bio, makes it subsidiary | strategic transactions | high | — | — |
| 18 Aug 2026 · Deutsche Bank releases pledge on 7.39% Piramal Pharma shares | ownership changes | high | — | — |
| 10 Aug 2026 · Piramal Pharma to acquire additional 41 percent stake in Yapan Bio, making it subsidiary | strategic transactions | high | — | — |
| 10 Aug 2026 · Piramal Pharma schedules analyst and investor meetings for September 2026 | board shareholder meetings | low | — | — |
| 3 Aug 2026 · Piramal Pharma resumes operations at Ahmedabad plant after flood | capex operations | high | — | — |
| 31 Jul 2026 · Q1FY27 Earnings Call Transcript Now Available on Website | investor communications | medium | — | — |
| Where a broker report shows | This document shows | Why |
|---|---|---|
| A rating (BUY / ADD / REDUCE / SELL) |
| 18.0 |
| 12.4 |
| 25.2 |
| CIPLA LTD | 1,10,352 | 32.7 | 3.20 | 16.9 | 11.2 | 14.7 | 8.0 | 19.7 |
| LAURUS LABS LIMITED | 1,06,375 | 97.2 | 19.59 | 59.3 | 16.4 | 17.2 | 7.2 | 32.0 |
| DR. REDDY S LABORATORIES | 97,319 | 30.1 | 2.55 | 13.1 | 10.9 | 13.0 | 12.1 | 15.0 |
| AUROBINDO PHARMA LTD | 96,656 | 26.3 | 2.55 | 13.4 | 9.2 | 12.6 | 6.3 | 23.0 |
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| P/B | 3.4 | 3.3 | 86 of 163 | 48% |
| ROCE | (1.8) | 10.8 | 157 of 183 | 14% |
| ROE | (4.0) | 10.4 | 153 of 171 | 11% |
| Debt / Equity | 0.7 | 0.1 | 152 of 171 | 11% |
| EBITDA margin | 12.5 | 17.5 | 105 of 165 | 37% |
| Revenue growth | 17.4 | 16.3 | 77 of 161 | 53% |
| Profit growth | 15.1 | 30.9 | 96 of 158 | 40% |
| Market cap | 28073 | 839 | 24 of 182 | 87% |
| A state: the latest filed quarter and the measured reactions |
| an event is a fact; a rating is an opinion that requires SEBI RA registration |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.
